Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of RO7795068 for weight management in adults with obesity or overweight without type 2 diabetes
NL-OMON61109Phase 3Recruiting
- Sponsor
- Roche
- Start
- Jun 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zilebesiran in obesity and Overweight, sponsored by Roche. Primary endpoint: Percent change from baseline in body weight at Week 72. Started Jun 2026; status: recruiting.
02
Drugs
zilebesiran
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NL-OMON61109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61109.